drug · small molecule
rimegepant sulfate ODT
Marketedupdated 5mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval, with an approval for migraine disorder.
targets
Calcitonin gene-related peptide type 1 receptor
all catalysts(10)
approval · 10
Feb 27, 2020
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Aug 18, 2020
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
May 27, 2021
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Dec 8, 2021
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 31, 2022
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Apr 11, 2022
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Dec 12, 2024
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 21, 2025
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Aug 1, 2025
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Mar 16, 2026
approval
$PFE27.80-1.14%
NURTEC ODT (RIMEGEPANT SULFATE) — FDA approval
rimegepant sulfate ODT
→
Trials studying rimegepant sulfate ODT
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 25, 2033
~6.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Mar 25, 2039formulationUS 11083724
- Feb 27, 2034compositionUS 8314117
- Feb 25, 2033compositionUS 8759372
News(2)
- New guidelines on migraine prevention reflect increasing options for patients“There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released Monday.stat · 1mo ago
- Biohaven trades cash for ‘upside’ with $795M epilepsy drug dealFaced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.biopharma_dive · 1mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that